Discussion
All 25 participants in the Phase 3 Embolden study have received their doses of NGN-401, Neurogene’s experimental gene therapy for Rett syndrome, surpassing the trial’s initial enrollment target ahead of schedule. “We are pleased to have completed dosing in the Embolden trial of NGN-401 within our original timeline while…